Abstract
148P Neoadjuvant EGFR-TKI combined with chemotherapy improves the complete response rate in operable EGFR-mutant NSCLC patients: A multicenter real-world study
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have